Immunovant’s

Immunovant’s

Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions. Learn more

Launch date
Employees
Market cap
CAD5.9b
Enterprise valuation
CAD5.2b (Public information from Sep 2024)
New York City New York (HQ)
Authorizing premium user...